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Viral quasispeciesThe HIV-1 quasispecies in peripheral blood mononuclear cells (PBMC) is considered to be a mix of actively
replicating, latent, and archived viruses and may be genetically distinct from HIV-1 variants in plasma that
are considered to be recently produced.
Here we analyzed the genetic relationship between gp160 env sequences from replication competent clonal
HIV-1 variants that were isolated from PBMC and from contemporaneous HIV-1 RNA in serum and HIV-1
proviral DNA in PBMC of four longitudinally studied therapy naïve HIV-1 infected individuals.
Replication competent clonal HIV-1 variants, HIV-1 RNA from serum, and HIV-1 proviral DNA from PBMC
formed a single virus population at most time points analyzed. However, an under-representation in serum
of HIV-1 sequences with predicted CXCR4 usage was sometimes observed implying that the analysis of viral
sequences from different sources may provide a more complete assessment of the viral quasispecies in
peripheral blood in vivo.unology M01-120, Academic
The Netherlands. Fax: +31 20
uitemaker).
mmunology, The University of
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During the course of HIV-1 infection virus replication and viral
turnover are high (Ho et al., 1995; Wei et al., 1995) which, in
combination with the error-prone nature of the HIV-1 reverse
transcriptase and its lack of proofreading, contribute to the high
genetic variability of HIV-1 and result in a continuous emergence of
new HIV-1 variants (Preston et al., 1988; Roberts et al., 1988). The
random generation of viral mutants facilitates escape from host
immune pressure and antiviral drugs, and selection for biological
properties such as co-receptor use and replication capacity.
The half life of HIV-1 in plasma is about 1.3 h indicating that virions
present in this compartmenthavebeenproduced very recently (Mittler et
al., 1999). The CD4+ T cell subset in peripheral blood mononuclear cells
(PBMC) is one of the targets for HIV-1, and, once infected, produces newviral progeny, part of which will be replication competent and likely to
contribute to the viral quasispecies found in plasma. Viruses produced in
other anatomical compartments may however also contribute to the
composition of the viral population in plasma, at least to someextent or in
certain disease stages. While plasma is considered to harbor recently
produced virus variants, PBMC are considered to harbor a combination of
recently produced and archived virus variants as they accumulate
integrated viral DNA (Chun et al., 1997; Chun et al., 1998; Chun et al.,
1995). Taken together, this would imply that the genetic composition of
the viral populations derived from plasma and PBMC may be different.
Whereas sections of the viral genome can be functionally evaluated
using recombinant pseudovirus assays, the study of biological proper-
ties of full-length replication competentHIV-1 requires virus isolation in
vitro. Given that the direct isolation of full-length replication competent
viruses from plasma is not very efﬁcient (Falk et al., 1987; Levy et al.,
1985; Michaelis and Levy, 1987; Salahuddin et al., 1985), virus isolation
is usually done by coculturing of patient PBMCwith stimulated healthy
donor PBMC (Hollinger et al., 1992; Van't Wout et al., 2008). However,
during virus isolation in bulk culture, the patient's HIV-1 variant that is
most ﬁt for replication in PBMC in vitro will be rapidly selected and
outgrow the less ﬁt virus variants that co-existed in the patient in vivo
(Kusumi et al., 1992; Meyerhans et al., 1989; Spira and Ho, 1995;
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limiting numbers of HIV-1 infected patient PBMC and stimulated
healthy donor PBMC are mixed in multiple parallel cocultures. This
procedure allows for the isolation of multiple replication competent
clonal HIV-1 variants (CV) from a single PBMC sample (Schuitemaker et
al., 1992) and avoids outgrowth and loss of slowly replicating variants
(Van't Wout et al., 2008).
To investigate the genetic relationship between viral variants
derived from the cell-free (serum) and cell-associated (PBMC) virus
pool and to examinewhether CV are representative for the replication
competent viral quasispecies in peripheral blood, we compared HIV-1
gp160 env sequences from replication competent CV with contem-
poraneous viral gp160 env sequences derived directly from serum
(viral RNA) and PBMC (proviral DNA) in a longitudinal study of 4
combined antiretroviral therapy (cART) naïve HIV-1 infected indivi-
duals throughout their course of infection.
Results
Phylogenetic analysis of gp160 env sequences from viral RNA in serum,
PBMC proviral DNA and clonal HIV-1 variants isolated from PBMC
Neighbor-joining phylogenetic tree analysis of gp160 env nucle-
otide sequences from all four patients and a reference sequence panelFig. 1.Maximum-likelihood tree of gp160 env sequences from viral RNA in serum, PBMC pro
the correlation of root-to-tip divergence as a function of sampling time. Bootstrap support w
indicates branch length corresponding to 0.01 substitutions per site.from different HIV-1 subtypes showed monophyletic clustering per
patient of sequences derived from viral RNA in serum (serum-RNA),
proviral DNA in PBMC (PBMC-DNA) and replication competent PBMC-
derived clonal HIV-1 variants (CV) with high bootstrap support
(values between 80 and 100), indicating absence of cross-contami-
nation between patient samples (data not shown).
To better examine the intra-host genetic relationship between the
HIV-1 quasispecies in serum-RNA, PBMC-DNA, and CV, maximum
likelihood (ML) trees were constructed with gp160 env sequences
from each patient separately. Tree topologies revealed temporal
structure in all four patients: sequences derived from serum-RNA,
PBMC-DNA or CV that had been sampled at the same time tended to
cluster together, and sequences from samples collected later in
infection showed greater divergence from the root of the tree. The
degree of intermingling of sequences from the three different sources
varied between patients and per time point. For patient A (Fig. 1), we
observed separate clustering of PBMC-DNA sequences at the ﬁrst and
third time point, respectively, but intermingling of the PBMC-DNA
sequences, mainly with CV sequences, at later time points. Sequences
from serum-RNA and CV from the ﬁrst four time points intermingled,
but later serum-RNA sequences clustered separately from both
contemporary PBMC-DNA and CV sequences, especially at the last
time point where they formed a well supported monophyletic cluster
that considerably diverged from the other sequences. In patient Bviral DNA and clonal HIV-1 variants. ML tree was rooted using the root that maximized
ith value N70% is shown. * indicate archived sequences. The scale bar (horizontal line)
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point intermixed with CV sequences. At the third and fourth time
point, viral sequences from all three sources were interspersed. The
tree also showed that the majority of serum-RNA sequences from the
ﬁrst two time points and two PBMC-DNA sequences from the third
time point formed separate phylogenetic lineages. Only two serum-
RNA sequences from the ﬁrst and second time point, respectively,
clustered with sequences from later serum-RNA samples, and with all
the CV and the majority of PBMC-DNA sequences. All serum samples
were processed separately from the PBMC samples and the CV,Fig. 2.Maximum-likelihood tree of gp160 env sequences from viral RNA in serum, PBMC pro
the correlation of root-to-tip divergence as a function of sampling time. Bootstrap support w
indicates branch length corresponding to 0.01 substitutions per site.excluding contamination between samples from the three different
sources and implying that the two clusters of viral env sequences from
early serum-RNA samples and the two PBMC-DNA sequences from
the third time point of patient B had indeed evolved independently
from the other sequences of this patient. In patients C and D (Figs. 3
and 4), intermingling of sequences from the three different sources
could be observed at all time points. However, similar to the
observation for patient B, ﬁve sequences from serum-RNA of the
ﬁrst three time points of patient C clustered separately from the
remainder of the sequences of that patient.viral DNA and clonal HIV-1 variants. ML tree was rooted using the root that maximized
ith value N70% is shown. * indicate archived sequences. The scale bar (horizontal line)
Fig. 3.Maximum-likelihood tree of gp160 env sequences from viral RNA in serum, PBMC proviral DNA and clonal HIV-1 variants. ML tree was rooted using the root that maximized
the correlation of root-to-tip divergence as a function of sampling time. Bootstrap support with value N70% is shown. * indicate archived sequences. The scale bar (horizontal line)
indicates branch length corresponding to 0.01 substitutions per site.
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formed a monophyletic cluster irrespective of the time of sampling.
Interestingly, sequences with an X4 signature were only obtained from
PBMC-DNA and CV.
Few sequences per patientwere identiﬁed as archived (markedwith *
in the phylogenetic tree) as they clustered with sequences from earlier
time points and had diverged less from the root of the tree than other
sequences from the same time point. We found a total of 2 archived
sequences in serum-RNA (in patients C and D), 4 in PBMC-DNA (1 in
patient A and3 in patient C) and6 in CV (2 inpatient B and4 inpatientD).Gene ﬂow between sequences from viral RNA in serum, PBMC proviral
DNA and clonal HIV-1 variants
Compartmentalization tests are generally used to detect a
restriction of gene ﬂow between viral subpopulations (Zarate et al.,
2007), in which case each virus subpopulation, generally coming from
different anatomical compartments, can evolve independently and
become genetically distinct. Here, we used these tests to determine
whether there was evidence for frequent gene trafﬁcking between
virus variants derived from serum-RNA, PBMC-DNA and CV as if they
Fig. 4.Maximum-likelihood tree of gp160 env sequences from viral RNA in serum, PBMC proviral DNA and clonal HIV-1 variants. ML tree was rooted using the root that maximized
the correlation of root-to-tip divergence as a function of sampling time. Bootstrap support with value N70% is shown. * indicate archived sequences. The scale bar (horizontal line)
indicates branch length corresponding to 0.01 substitutions per site.
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restricted implying differences in genetic composition and indepen-
dent evolution between virus variants of the different sources.
ML trees and alignments based on envelope sequences of
each patient were analyzed with six different compartmentalization
tests: SM, r, rb and AI that are all based on tree topology, and F_St and
Snn that are based on pairwise genetic distances between viral
sequences.
The 4 tree-based tests, which allow for simultaneous comparison
of more than two sequence populations, were used for the analysis ofgene trafﬁcking between serum-RNA, PBMC-DNA and CV. In addition,
a pairwise comparison of two sources (serum-RNA vs. CV, CV vs.
PBMC-DNA and serum-RNA vs. PBMC-DNA) was performed with all
six tests (Table 1). Comparisons included only the time points at
which sequences from all the sources compared were available. Given
the different sensitivities and frequently discordant predictions of the
different methods (Zarate et al., 2007), for each comparison we took a
majority consensus approach meaning that the signal for compart-
mentalization was only considered positive when more than half of
the tests gave signiﬁcant P-values.
Table 1
Results of compartmentalization tests per patient and time point.
Patient Corr. coefﬁcients Fraction of signiﬁcant
tests for compartmentalization
SM AI r rb Snn F_St
A ALL 0.001 0.019 ns ns 2/4
SE vs CV ns ns ns ns 0.013 ns 1/6
CV vs PB 0.003 0.009 ns ns b0.0001 ns 3/6
SE vs PB b0.0001 0.003 ns ns b0.0001 ns 3/6
B ALL b0.0001 b0.0001 0.003 0.001 4/4
SE vs CV b0.0001 0.016 0.009 ns b0.0001 b0.0001 5/6
CV vs PB b0.0001 0.001 ns ns b0.0001 ns 3/6
SE vs PB b0.0001 b0.0001 0.001 0.001 b0.0001 b0.0001 6/6
C ALL b0.0001 b0.0001 ns ns 2/4
SE vs CV 0.030 ns ns ns 0.002 ns 2/6
CV vs PB b0.0001 0.008 ns ns b0.0001 ns 3/6
SE vs PB b0.0001 0.002 ns ns b0.0001 ns 3/6
D ALL 0.001 0.025 ns ns 2/4
SE vs CV 0.041 ns ns ns 0.015 ns 2/6
CV vs PB 0.005 ns ns ns b0.0001 ns 2/6
SE vs PB 0.008 ns ns ns 0.003 ns 2/6
Compartmentalization analysis was performed with 4 tests (SM, AI, r and rb) when sequences of all three sources (serum-RNA (SE); clonal HIV-1 variants (CV); PBMC-DNA (PB))
were compared (ALL). Subsequently, all 6 tests were implemented on the comparison of each pair of sources separately (SE vs CV, CV vs PB and SE vs PB) including only the time
points at which sequences from the two sources compared were available. The signal for compartmentalization was only considered positive when more than half of the tests gave a
signiﬁcant P-value (ﬁlled cells). P-values b 0.05 were considerate signiﬁcant. ns: not signiﬁcant.
SM: Slatkin-Madison; AI: Simmonds Association Index; r: distance between to sequences as the number of tree branches separating them in the phylogenetic tree; rb: cumulative
genetic distance between the sequences; Snn: Nearest-neighbor statistic; F_St: Wright's measure of population subdivision.
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was detected in the simultaneous analysis of all three sources of viral
sequences (2 of 4 tests with a signiﬁcant P-value) suggesting that the
viruses from serum-RNA, PBMC-DNA and CV in these patients are likely
to form a single virus population. This was supported by the
comparisons of each pair of sequence sources separately in which ≤3
of 6 tests gave signiﬁcant P-value. For patients A and C, we obtained a
borderline signiﬁcant result (3 of 6 tests positive for compartmental-
ization) for the compartmentalization analysis between PBMC-DNAand
either serum-RNA or CV. This coincided with a certain degree of
segregation, at some time points, between PBMC-DNA and either
serum-RNA or CV sequences in the phylogenetic tree of those two
patients. For patient B, signiﬁcant P-values were obtained in all 4
compartmentalization tests in which sequences from serum-RNA,
PBMC-DNA, and CV were analyzed together. Analysis of gene ﬂow for
each pair of sequence sources separately showed that compartmental-
ization occurred between serum-RNA and either PBMC-DNA or CV (≥5
of 6 tests with a signiﬁcant P-value). This was supported by the tree
topology in which only two serum sequences from the ﬁrst and second
timepoints clusteredwith the sequences from later serum-RNAsamples
and all the CV and themajority of PBMC-DNA sequences, while all other
serum-RNA sequences from the ﬁrst and second time point and two
PBMC-DNA sequences from the third time point formed a separate
cluster.
None of the statistical tests reported here were adjusted for multiple
comparisons. While it is customary to adjust P-values for multiple
comparisons when making positive claims, our use of uncorrected P-
values is conservative with respect to the negative conclusions in
this study (i.e., that compartmentalization was minimal).
Diversity of HIV-1 gp160 env sequences from RNA in serum, PBMC
proviral DNA and clonal HIV-1 variants
Wenext compared themeanpairwise genetic distance per timepoint
(diversity) within the viral gp160 env sequences derived from serum-
RNA, PBMC-DNA, and CV (Fig. 5, and summary in Table 2 and
Supplementary Table A2).
Sequence diversity within serum-RNA, CV, and PBMC-DNA, which
was compared at time points where sequences from all three sources
were available, was similar at 1 of 3 time points in patients A and D
and at 2 of 4 time points in patients B and C (Table 2). In patients A andC, sequence diversity was signiﬁcantly lower in PBMC-DNA at one of
the time points (ﬁrst and fourth time point, respectively). Sequence
diversity in serum-RNA was signiﬁcantly lower at the last time point
of patient A and signiﬁcantly higher at the second time point of
patient C. For patients B and D, sequence diversity in serum-RNA was
signiﬁcantly lower at one of the time points (third and ﬁrst time point,
respectively) and PBMC-DNA had the highest, and CV the lowest
sequence diversity at the other time point (ﬁrst and third time point
for patients B and D, respectively; Table 2).
Diversity between serum-RNA and CV could be compared at 5, 4, 4,
and 3 time points for patients A, B, C, and D, respectively (Table 2). At 9 of
these16 timepoints, corresponding to33–75%of the timepoints analyzed
per patient (Supplementary Table A2), sequence diversity between
serum-RNA and CV was similar.
Diversity between CV and PBMC-DNA could be compared at 4 time
points for patients A, B and C and at 5 time points for patients D (Table 2).
At 11 of those 17 time points, corresponding to 50–75% of the time points
analyzed per patient, PBMC-DNA and CV had similar sequence diversity
(Supplementary Table A2).
Diversity in serum-RNA and PBMC-DNA could be compared at 3
time points for patients A and D, and at 4 time points for patients B
and C (Table 2). Similar sequence diversity in serum-RNA and PBMC-
DNA was found at 6 of the in total 14 time points at which the
comparison was performed, corresponding to 33–50% of the time
points that were analyzed per patient (Supplementary Table A2).
Differences in sequence diversity between serum-RNA, CV and
PBMC-DNA were detected in the pairwise comparisons of the different
sources under study at 25–67% time points analyzed per patient. Those
differences could not be attributed to a higher or lower sequence
heterogeneity of one of the sources in particular, neither to any patient-
speciﬁc patterns.
No correlation was found between the viral load at a certain time
point and the diversity of sequences from serum-RNA, PBMC-DNA and
CV (data not shown).
Divergence of HIV-1 gp160 env sequences from RNA in serum, PBMC
proviral DNA and clonal HIV-1 variants
Subsequently, we compared per time point the mean pairwise
genetic distance between gp160 env sequences from serum-RNA and
PBMC-DNA, serum-RNA and CV, and PBMC-DNA and CV (divergence)
Fig. 5. Pairwise genetic distances per time point within (diversity) and between (divergence) gp160 env sequences from viral RNA in serum (SE), PBMC proviral DNA (PB) and clonal
HIV-1 variants (CV). Mean pairwise distances were calculated per time point and compared using the Mann–Whitney test for independent samples. P-values b 0.05 were considered
signiﬁcant. Patient A (A), patient B (B), patient C (C), patient D (D).
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separately (Fig. 5, and summary in Table 2 and Supplementary
Table A2).
For patients A, C and D, the divergence between sequences from
serum-RNA and CV was similar to the diversity within sequences from
either serum-RNA or CV in 33–60% of the time points analyzed. For
patient B, divergence between serum-RNA and CV was always higher
than diversity in either serum-RNA and/or CV.
Divergence between CV and PBMC-DNA sequences was similar to
the diversity within the sequences from either CV or PBMC-DNA in
40–100% of the time points analyzed per patient.
Divergence between sequences from serum-RNA and PBMC-DNA
was higher than the diversity within serum-RNA and/or PBMC-DNA
in 33–75% of the time points analyzed per patient.
The increased divergence between serum-RNA and both CV and
PBMC-DNA for patients A and B coincided with the presence ofCXCR4-using CV and sequences with an X4 genotype in PBMC-DNA
but not in serum-RNA. Indeed, sequences with an X4 signature
clustered separately from R5 sequences in the ML tree (Figs. 1 and 2).
Divergence between serum-RNA and both CV and PBMC-DNA at
the ﬁrst two time points of patient B could be attributed to the
separate clustering of most of the early serum-RNA sequences in the
ML tree (Fig. 2).Co-receptor use of clonal HIV-1 variants and predicted co-receptor use of
sequences derived from viral RNA in serum and PBMC proviral DNA
CXCR4 usage of CV was determined by their ability to replicate in
the MT-2 cell line (Van't Wout et al., 2008) and conﬁrmed with
prediction tools that are based on V3 amino acid sequences (Jensen et
al., 2003; Jensen et al., 2006; Sing et al., 2007). The same prediction
Table 2
Comparison of mean gp160 env pairwise genetic distances within (diversity) and between (divergence) sequences from serum-RNA, PBMC-DNA and clonal HIV-1 variants per time
point and patient.
Patient Time point Diversity Divergence
serum-RNA/CV CV / PBMC-DNA serum-RNA/PBMC-DNA
A 1 SE=CVNPB SEvsCV=SE=CV CVvsPB=CV/CVvsPB=PB SEvsPB=SENPB
2 SE=CV SEvsCV=SE=CV n.a. n.a.
3 CVNPB* SEvsCV=CV* CVvsPB=CVNPB SEvsPBNPB *
4 SEbCV SEvsCV=CVNSE n.a. n.a.
5 SE=CV=PB SEvsCV=SE=CV CVvsPB=CV=PB SEvsPB=SE=PB
6 SEbCV=PB SEvsCVNCVNSE CVvsPB=CV=PB SEvsPBNPBNSE
B 1 PBNSENCV SEvsCVNSENCV CVvsPB=CV=PB SEvsPBNPBNSE
2 SE=CV=PB SEvsCVNSE=CV CVvsPB=CV=PB SEvsPBNSE=PB
3 CV=PBNSE SEvsCV=CVNSE CVvsPB=CV=PB SEvsPBNPBNSE
4 SE=CV=PB SEvCVNSE/SEvsCV=CV CVvsPB=CV=PB SEvsPB=SE=PB
C 1 SE=CV=PB SEvsCV=SE=CV CVvsPB=CV=PB SEvsPBNSE/SEvsPB=PB
2 SENCV=PB SEvsCV=SENCV CVvSPBNBC=PB SEvsPB=SENPB
3 SE=CV=PB SEvsCV=SE=CV CVvsPB=CV=PB SEvsPB=SE=PB
4 SE=CVNPB SEvsCVNSE/SEvsCV=CV CVvSPB=BCNPB SEvsPB=SENPB
D 1 CV=PBNSE CVNSEvCVNSE CVvsPBNCV/CVvsPB=PB SEvsPB=PBNSE
2 SE=CV=PB SEvsCV=SE=CV CVvsPB=CV=PB SEvsPB=SE=PB
3 PBNSENCV SEvsCV=SENCV CVvsPB=CVNPB SEvsPB=SE/SEvsPB=PB
4 CVNPB n.a. CVvsPB=CVNPB n.a.
5 CV=PB* SEvsCV=CV* CVvsPB=CV=PB SEvsPBNPB*
SE: diversity in serum-RNA; CV: diversity in clonal HIV-1 variants; PB: diversity in PBMC-DNA; SEvsCV: divergence between serum-RNA and CV; CVvsPB: divergence between CV and PBMC-
DNA; SEvsPB: divergence between serum-RNA and PBMC-DNA.= indicates no signiﬁcant difference betweenmean pairwise genetic distances; b or N indicate signiﬁcant differences between
mean pairwise genetic distances (P-value b 0.05); bold indicates no signiﬁcant differences between any of the comparisons. * Time point with only one serum sequence available.
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obtained from serum-RNA and PBMC-DNA.
Co-receptor use of CV and viral sequences derived from serum-
RNA and PBMC-DNA was compared for patients who harbored both
CCR5- and CXCR4-using variants (patients A and B, and four
additional patients (E, F, G and H) from whom gp120 (C2–C4)
envelope unpublished sequences from serum-RNA and CV were
available (see Supplementary Table A1 and Supplementary Material
andMethods)). Fig. 6 shows percentages and absolute numbers of R5/
CCR5-using and X4/CXCR4-using variants in serum-RNA and CV for
all six patients and additionally in PBMC-DNA for patients A and B.
Absence or underrepresentation of X4 variants in serumwas observed
in patients from whom only low numbers of clonal CXCR4-using HIV-
1 variants could be isolated (patients A, B, E and F). Patients A, B and E
completely lacked X4 env sequences in serum (Fig. 6A, B and C). For
patient F, X4 sequences were found in serum at the time point close to
the estimated emergence of CXCR4-using variants but were no longer
detected in later stages of infection (Fig. 6D). Interestingly, in patients
A and B, X4 sequences were detected in PBMC-DNA at the same time
points at which CXCR4-using CV could be isolated. Patients from
whom higher numbers of CXCR4-using clonal HIV-1 variants could be
isolated (patients G and H; Fig. 6E and F) had similar percentages of
X4/CXCR4-using variants in serum and CV.
Discussion
The cell-free and cell-associated HIV-1 pool in peripheral blood
may potentially differ in genetic composition as the virus variants
from plasma are generally considered to represent the recently
produced virus population in vivo, while PBMC are considered to
harbor a mix of recently produced viruses and archived viruses. To
address this, we compared evolution and genetic variability of cell-
associated virus (proviral DNA from PBMC (PBMC-DNA) and
replication competent clonal HIV-1 variants (CV) isolated from
PBMC) and cell-free virus in serum (serum-RNA).
Phylogenetic analysis of gp160 env nucleotide sequences revealed
that sequences derived from serum-RNA, PBMC-DNA, and CV from the
same time point generally clustered together and that divergence to
the most recent common ancestor was in general greater for
sequences collected at later time points of infection, independentlyof the source from which they were obtained. Intermingling of
sequences from the three sources was observed in all patients,
although segregation of sequences from serum-RNA or PBMC-DNA
was found at some time points. Firstly, in patients B and C, some of the
serum-RNA sequences evolved independently with no descendents at
late stages of the infection, suggestive for negative selection of these
viruses or only transient production of these viruses from another
body compartment. Secondly, in patients A and B who showed
emergence of CXCR4-using variants, the X4/CXCR4-using variants,
which clustered separately from the R5/CCR5-using variants in the
phylogenetic tree, were detected in patient PBMC-DNA and CV but not
in serum-RNA. The segregation between sequences from serum and
PBMC-DNA and/or CV after the emergence of CXCR4-using variants in
these patients could be attributed to the absence of X4 variants in
serum. Finally, a low degree of intermingling of viral sequences from
PBMC-DNA with sequences of the other two sources was observed at
time points where PBMC-DNA sequences were very homogeneous.
This could either reﬂect low sequence diversity in PBMC-DNA at
speciﬁc time points or limitations in the detection of minor variants.
In 3 out of 4 patients (A, C and D), we found evidence for frequent
gene trafﬁcking between serum-RNA, PBMC-DNA and CV, albeit that
compartmentalization between PBMC-DNA and either serum-RNA or
CV was borderline signiﬁcant for patients A and C, which coincided
with a certain degree of segregation between some of the sequences
from PBMC-DNA and the other sources in the phylogenetic trees.
Overall however, our data support that in each of these patients,
sequences from the three sources belonged to the same viral
population. In patient B, we detected a restriction of gene trafﬁcking
between serum-RNA and both PBMC-DNA and CV. This restriction is
probably the result of negative selection of most of the early viruses in
serum, in combination with the differential evolution of viral
coreceptor use in serum and PBMC. This implies that the cell-free
(serum) and cell-associated (PBMC) viral quasispecies can occasion-
ally be different and therefore not always reﬂecting the same fraction
of viruses present in peripheral blood at a certain time point.
Previous studies have shown the effect of PBMC cultures for bulk
virus isolation on the composition of virus populations (Kusumi et al.,
1992; Meyerhans et al., 1989; Spira and Ho, 1995; Voronin et al.,
2007). While some argued that a minor HIV-1 variant present in vivo
(Meyerhans et al., 1989) or a variant not even detected in the patient
Fig. 6. Percentage of predicted R5/CCR5-using variants and predicted X4/CXCR4-using variants in serum RNA (SE), PBMC proviral DNA (PB) and clonal HIV-1 variants (CV). All CV
were tested for the ability to use CXCR4 in the MT-2 assay and results were conﬁrmed with co-receptor use prediction based on the V3 amino acid sequences and the PSSM matrix
and using the geno2pheno[coreceptor] method (FPR=5%). The same prediction methods were used to predict co-receptor use of viral sequences obtained from viral RNA in serum or
from proviral DNA in patient PBMC. Numbers on bars indicate percentages of predicted R5/CCR5-using variants and predicted X4/CXCR4-using variants per time point.
500 D. Edo-Matas et al. / Virology 405 (2010) 492–504(Kusumi et al., 1992) could dominate the co-culture in vitro, others
found that the major variant present in uncultured PBMCwas the one
persisting in the culture (Voronin et al., 2007). Indeed, bulk virus
isolation in vitro seems to select for one or few HIV-1 variants that
have optimal ﬁtness for replication in PBMC in vitro. Although the
clonal virus isolation procedure allows for the isolation of multiple
variants, there is still the concern that only a fraction of the virus
variants originally present in vivo may be selected and that novel
mutations may occur during culturing of the virus. We here show that
CV exhibit a sequence variability similar to contemporaneous viral
populations obtained from viral RNA in serum and PBMC proviral
DNA. When diversity between the three different sources differed,
this was not necessarily due to a higher or lower heterogeneity of
sequences from CV. Moreover, signiﬁcant divergence was found
between CV and the viral sequences derived from serum-RNA andPBMC-DNA, but comparable differences in divergence were also
observed between serum-RNA and PBMC-DNA. Therefore we con-
clude that CV are not a speciﬁc selection from the virus pool in blood
at the moment of sampling and that the sequence variation that may
have been introduced during culture in CV is limited. We are aware
that with the population sequencing methodology not all viral
variants present in the sample may have been detected and that we
therefore may have underestimated the actual sequence variability in
PBMC-DNA and serum-RNA. However, our approach at least demon-
strates a similar composition of the CV and the dominant virus
populations in serum-RNA and PBMC-DNA.
Differences in the genetic composition of virus populations from
serum-RNA and PBMC-DNA have mostly been reported for patients
receiving HAART. Drug-resistance mutations can be detected in
plasma before their occurrence in PBMC. More importantly, the
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prolonged suppression of plasma viremia, suggested a reservoir of
archived viruses in PBMC (Finzi et al., 1997; Wong et al., 1997). In our
present study, only a few sequences from PBMC-DNA and CV, and
interestingly in two patients also from serum-RNA, were identiﬁed as
potentially archived viruses. This suggests that in the absence of
therapy, PBMC proviral DNA reﬂects mostly the actively replicating
virus population and that CV can be considered an accurate reﬂection
of the replication competent viruses at a givenmoment, not excluding
that a low percentage of archived latent viruses may be recovered
with the clonal virus isolation procedure.
Our observation that CXCR4-using variants may be more common
in PBMC than in serum-RNA is in agreement with a previous cross-
sectional study from Verhofstede et al. (2009). We conﬁrm and
extend those observations by showing in longitudinal samples that X4
variants were not always detected in serum when only low numbers
of CXCR4-using CV were obtained. We have previously reported
that early CXCR4-using HIV-1 variants have a higher sensitivity to
antibody neutralization than their co-existing CCR5-using variants
(Bunnik et al., 2007) and several studies have suggested that HIV-
speciﬁc immune responses may promote the preferential survival of
CCR5-using strains (Bou-Habib et al., 1994; Callaway et al., 1999;
Cheng-Mayer et al., 1988; Cornelissen et al., 1995). This may suggest
that a cell-free state of CXCR4-using viruses is incompatible with
neutralizing humoral immunity, which could explain their absence or
underrepresentation in serum and their restriction to cell-to-cell
spread in PBMC. As the contribution of CXCR4-using HIV-1 to the total
virus population may increase over time (Koot et al., 1996), the equal
distribution of X4 sequences in serum-RNA and CV in individuals with
higher numbers of CXCR4-using variants may reﬂect the selection of
neutralization resistant CXCR4-using variants that can persist in
plasma.
The major advantage of working with replication competent CV is
that biological properties of the virus can be studied in the context of
the original genetic background and the complete viral genome,
which obviously is not the case with cloned viral gene fragments from
plasma in the background of a molecular HIV-1 clone. Our present
study shows that clonal HIV-1 variants isolated from PBMC may
equally represent the viral quasispecies in blood as sequences
obtained from serum and PBMC proviral DNA. However, certain
selective forces may drive differential evolution of the cell-free and
cell-associated virus pool, in which case, sequences from both sources
would be ideally required to obtain a more complete picture of the
viral quasispecies in peripheral blood in vivo.
Materials and methods
Patients and samples
Longitudinal blood samples from eight participants of the
Amsterdam Cohort Studies on HIV-1 infection and AIDS (http://
www.amsterdamcohortstudies.org) were used for this study. Patients
A, B, C and D were selected on the basis of available CV isolated from
PBMC at multiple time points in the course of infection, and the
availability of serum and DNA samples from most of these same time
points. Additionally, patients A and B were selected because they
developed CXCR4-using CV in their course of infection while patients
C and Dwere selected because they did not develop CXCR4-using HIV-
1 variants. To substantiate our ﬁndings on prevalence of X4/CXCR4-
using viruses in cell-free and cell-associated HIV-1 populations, four
additional patients, E, F, G and H, were selected because they
developed CXCR4-using HIV-1 variants during their course of
infection and because viral sequences from serum-RNA and CV were
available from multiple time points covering their course of HIV-1
infection. Time from documented or imputed seroconversion (SC)
(Geskus, 2000) at the moment of sampling and number of sequencesanalyzed are indicated in Supplementary Table A1 for each patient.
Patients did not receive cART during the study period. For each patient
longitudinal data on CD4 counts and viral load are shown in
Supplementary Fig. A1.
The Amsterdam Cohort Studies are conducted in accordance with
the ethical principles set out in the declaration of Helsinki and written
informed consent was obtained prior to data collection. The study was
approved by the AcademicMedical Center institutional medical ethics
committee.
Isolation of replication competent clonal HIV-1 variants
Replication competent clonal HIV-1 variants (CV)were obtained in
cocultures of longitudinally sampled patient PBMC and 2- to 3-day
phytohemagglutinin (PHA) stimulated PBMC from a healthy donor
(PHA-PBMC) as described previously (Schuitemaker et al., 1992; Van't
Wout et al., 2008). In brief, PBMC from a healthy donor were
stimulated for 2–3 days in Iscove's Modiﬁed Dulbecco's Medium
(IMDM, Lonza) supplemented with 10% Fetal Calf Serum (FCS;
Hyclone), 1 μg/ml PHA (Welcome), 100 U/ml Penicillin and 100 U/ml
Streptomycin (Pen/Strep; Gibco Brl), 5 μg/ml Ciproﬂoxacin (Bayer) in a
culture ﬂask at a cell density of 5×106/ml. Increasing numbers of
patient PBMC (range 2500–40,000) were added to 105 PHA-PBMC (48
parallelmicro-cocultures per patient PBMCnumber) in aﬁnal volumeof
200 μl IMDM-IL2 medium (IMDM supplemented with 10% FCS, 100 U/
ml Penicillin and 100 U/ml Streptomycin, 10 U/ml rIL-2 (proleukin;
Chiron Benelux BV), 5 μg/ml Ciproﬂoxacin and 5 μg/ml polybrene
(Sigma)) for 28 days in a 96-well ﬂat-bottom microtiter plate. Every
week, culture supernatants were tested for virus production in an in-
house Gag p24 antigen capture enzyme-linked immunosorbent assay
(ELISA) (Tersmette et al., 1989). At the same time, half of the remaining
resuspended culture volumewas transferred to new 96-well plates and
fresh PHA-stimulated healthydonor PBMCwere added to propagate the
culture. If less than one-third of the 48 parallel mictro-cocultures per
patient PBMC number is positive for p24 production, then according to
Poisson distribution these cultures can be assumed to be infected with
progeny virus of one infected patient cell and, therefore, they are highly
likely to be clonal. Cultures of clonal viruses were expanded by
cocultivation of PBMC from p24 positive microcultures with 5×106
PHA-PBMC at a density of 1×106/ml IMDM-IL2 medium in a culture
ﬂask. From all patients, virus isolations were performed at 4 to 6 time
points spanning the course of infection.
HIV-1 RNA isolation from serum, cDNA synthesis and PCR ampliﬁcation
Serum RNA was isolated with the QIAamp Viral RNA Mini Kit
(Qiagen) according to the manufacturer's protocol using 140 μl of
serum. Isolated RNA was eluted in a ﬁnal volume of 40 μl. Viral RNA
(10 μl) was ampliﬁed in an RT-PCR reaction with a total volume of
50 μl using Superscript III One-step RT-PCR with High Fidelity
Platinum Taq (Invitrogen) and primers EnvA (fw) (5'-GGC TTA GGC
ATC TCC TAT GGC AGG AAG AA-3') and Env3Rlong (rev) (5'-GGT GTG
TAG TTC TGC CAA TCA GGG AAG WAG CCT TGT GTG-3'). The RT step
was performed at 55 °C for 1 h, followed by a 2 min denaturation at
95 °C and 40 PCR ampliﬁcation cycles of 95 °C for 20 s, annealing for
20 s, and 68 °C extension for 4 min. Annealing temperatures were
65 °C for 3 cycles, 60 °C for 11 cycles and 55 °C for 26 cycles. A 25-cycle
nested PCR reaction was performed on samples that generated
insufﬁcient ﬁrst round product to be visualized by electrophoresis
using Advantage 2 Polymerase mix (Clontech) with internal primers
Env_2Flong (fw) (5'-GGT TAA TTG ATA GAA TWA GRG AAA GAG CAG
AAG ACA GTG GCA ATG-3') and Nef5 (rev) (5'-CCCWTC CAG TCC CCC
CTT TTC TTT TAA AAA G-3'), annealing at 55°C. Gp160 env PCR
products were gel puriﬁed using the QIAquick Gel Extraction Kit
(Qiagen) according to the manufacturer's protocol.
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Total DNA was isolated from 3×106 PBMC from HIV-1 infected
patients using a modiﬁcation of the L6 isolation method (Kootstra and
Schuitemaker, 1999). Precipitated DNA was dissolved in 100 μl of
distilledwater and 5 μl were used for gp160 env gene ampliﬁcationwith
the Advantage 2 Polymerase Mix (Clontech) and primers targeting env
(EnvA and Env_3Rlong) in a total reaction volume of 50 μl. Reactions
were as described for the RT-PCR with omission of the 55 °C RT step. A
25-cycle nested PCR reaction was performed with internal primers
Env_2Flong and Nef5 on samples that generated insufﬁcient ﬁrst round
product to be visualized by electrophoresis as described in the previous
section. The PCR product was gel puriﬁed using the QIAquick Gel
Extraction Kit (Qiagen) according to the manufacturer's protocol.
Cloning and sequencing of gp160 env PCR products from serum and
PBMC
Puriﬁed PCR products were cloned into the pCR®4-TOPO vector
from the TOPO TA Cloning® Kit for Sequencing (Invitrogen) according
to the manufacturer's protocol. Following transformation into One-
shot TOP10 chemically competent Escherichia coli, positive transfor-
mants were selected on LB plates with ampicillin. Eight colonies per
sample were picked and shipped to Functional Biosciences, Inc,
Madison, WI, USA for sequencing.
Plasmid DNA was extracted and sequences were analyzed on an
Applied Biosystems 3730xl Genetic Analyzer. Primers used for
sequencing are speciﬁed in the Supplementary Methods section.
Viral load at the time of sampling did not correlate with the diversity
of the sequences obtained from serum-RNA or PBMC-DNA, excluding
template resampling as a reason for low diversity in some samples.
DNA isolation, PCR ampliﬁcation and sequencing of gp160 env from
clonal HIV-1 variants
Total DNA was isolated from 1×10 6 healthy donor PBMC in vitro
infected with clonal HIV-1 isolates, using a modiﬁcation of the L6
isolation method (Kootstra and Schuitemaker, 1999) and gp160 env
gene ampliﬁcation was performed with one outer PCR with primers
TB3 (fw) (5'-GGCCTTATTAGGACACATAGTTAGCC-3') and TBC (rev)
(5'-GCTGCCTTGTAAGTCATTGGTCTTAAAGG-3') and a nested PCR with
primers TB2 (fw) (5'-CTCTACAATACTTGGCACTAGCAGC-3') and TBA
(rev) (5'-CCTCTTGTGCTTCTAGCCAGGCACA-3') using the expand high
ﬁdelity Taq polymerase kit (Roche) and the following ampliﬁcation
cycles: 2 min 30 s 94 °C, 9 cycles of 15 s 94°C, 45 s 53°C, 6 min 68 °C,
30 cycles of 15 s 94 °C, 45 s 58 °C, 6 min 68 °C, followed by a 10-min
extension at 68 °C and subsequent cooling to 4 °C. PCR products were
puriﬁed using ExoSAP-IT (USB) according to the manufacturer's
protocol. Sequencing conditions were 5 min at 94 °C, 30 cycles of 15 s
at 94 °C, 10 s at 50 °C, 2 min at 60°C and a 10 min extension at 60 °C.
Sequencing was performed using BigDye Terminator v1.1 Cycle
Sequencing kit (ABI Prism, Applied Biosystems) according to the
manufacturer's protocol. Primers used for sequencing are speciﬁed in
the Supplementary Methods section. Sequences were analyzed on the
3130 xl Genetic Analyzer (Applied Biosystems).
Prediction and determination of co-receptor usage
All study participants were routinely tested at approximately 3
monthly intervals for the presence of replication competent CXCR4-
using HIV-1 variants in PBMC using the MT-2 assay (Koot et al., 1992).
In brief, 1×106 patient PBMC were co-cultured with 1.6×106 MT-2
cells during 3–4 weeks in duplicate and cultures were periodically
screened for syncytia formation and for p24 antigen production in the
culture supernatant. The midpoint between the last negative and ﬁrstpositive MT-2 test was estimated as the date of ﬁrst emergence of
CXCR4-using viruses in the patient.
All isolated clonal HIV-1 variants were tested for their ability to use
CXCR4 in the MT-2 assay (Van't Wout et al., 2008). For patient E,
CXCR4-using variants were isolated via clonal virus isolation whilst
the MT-2 test performed on the same PBMC sample was still negative
at that time point, which is most likely related to the lower number of
cells that is used for the MT-2 assay (1×106 patient PBMC) as
compared to the clonal viral isolation procedure (up to 5×106
patients PBMC). Indeed, the relative contribution of CXCR4 using HIV-
1 to the total viral load may initially be low. CXCR4-using phenotype
of CV was conﬁrmed with V3 amino acid sequences and the PSSM
matrix (Jensen et al., 2003; Jensen et al., 2006) and using the
geno2pheno[coreceptor] method (FPR = 5%) (Sing et al., 2007). The
same predictionmethodswere used to predict co-receptor use of viral
sequences obtained from viral RNA in serum or from proviral DNA in
patient PBMC. Throughout the manuscript we use the term “CXCR4-
using” for CV for which actual CXCR4 usage has been demonstrated in
the MT2 cell-line, not excluding the possibility that these CV also have
the ability to use CCR5 or any other coreceptor. For sequences with a
predicted ability to use CXCR4we use the term “X4” since actual usage
of this coreceptor has not been experimentally proven. The term X4
does not exclude the possibility that the envelope has the ability to
also use CCR5 or any other coreceptor. The term “CCR5-using” is used
for CVwhich failed to infect theMT2 cell line and the term “R5” is used
for sequences with a predicted ability to use CCR5.
Phylogenetic analysis
Nucleotide sequences were aligned using ClustalW included in the
software package of BioEdit v.7.0.9 (Hall, 1999) (BioEdit v 7.0.5, Tom
Hall, Ibis Therapeutics, Carlsbad, CA) and edited manually.
Neighbor-Joining (NJ) tree (Saitou and Nei, 1987) for the gp160
envelope sequences from serum, proviral DNA from patient PBMC and
isolated clonal HIV-1 variants from the 4 patients under study and a
reference sequence panel from different HIV-1 subtypes obtained
from Los Alamos Database was constructed under the Hasegawa-
Kishino-Yano (HKY85) model of evolution (Hasegawa et al., 1985) in
PAUP* 4.0 beta 8 software package (Swofford, 2002) (http://paup.
csit.fsu.edu/). Phylogenetic conﬁdence was assessed by bootstrap
with 1000 replicates (data not shown).
The best-ﬁt nucleotide substitution model for every patient
sequence data set was selected by hierarchical likelihood ratio test
(hLTR) in Model Test 3.7 (Posada and Crandall, 1998) and imple-
mented in the construction of maximum likelihood (ML) trees for the
gp160 env region per patient. The heuristic search for the best tree
was performed using a NJ tree as starting tree and the TBR branch-
swapping algorithm. NJ trees were constructed under the HKY85
model with a transition/transversion ratio and the shape of the γ-
distribution estimated using maximum likelihood. ML trees were
rooted using the root that maximized the correlation of root-to-tip
divergence as a function of sampling time.
Analysis of genetic distance
To estimate diversity and divergence, pairwise nucleotide dis-
tances were calculated with the Kimura-2 parameter model of
evolution in the software package MEGA 4 (Tamura et al., 2007).
Mean pairwise distances were compared using the Mann–Whitney
test for independent samples (SPSS 16.0 software package).
Statistical tests for compartmentalization
Six different compartmentalization tests were used to determine
compartmentalization between sequences from viral RNA in serum,
from proviral DNA in PBMC, and from clonal HIV-1 variants. Four of
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(Slatkin and Maddison, 1989), Simmonds Association Index (AI)
(Wang et al., 2001) and Correlation Coefﬁcients (r and rb) (Critchlow
et al., 2000)) and two of them are based on pairwise genetic distances
between viral sequences (Wright's measure of population subdivision
(FST) (Hudson et al., 1992a; Hudson et al., 1992b; Slatkin, 1993) and
Nearest-neighbor statistic (Snn) (Hudson, 2000)). Compartmentali-
zation between sequences derived from the three sources was
analyzed with four tests (SM, AI, r and rb). In addition, a pairwise
comparison of sequences from two sources was performedwith all six
tests. Analyses were implemented in ML trees or alignments that
included only the gp160 env sequences from time points at which the
sources to be compared were available. ML trees were constructed as
described above.
Statistics and compartmentalization tests were implemented in
HyPhy as described (Zarate et al., 2007). Methods and parameters
implemented in Hyphy for each method are described in Supplemen-
tary Material and Methods.
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